Please assess the completion status of the following clinical trial:

Trial Title: Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with written consent by their own volition after being provided sufficient explanation for their participation in this clinical trial~* Patients 20 years or older at the time of their consent~* Patients with hypercholesterolemia as defined by any of the following criteria:~  * TC \>= 220 mg/dL;~ * LDL-C \>= 140 mg/dL;~ * Cholesterol-lowering treatment is necessary in accordance with the investigator's judgement when LDL-C \>= 100 mg/dL or TC \>= 180 mg/dL.~* Patients who have been diagnosed with acute coronary syndrome~* Patients with successful percutaneous coronary intervention (PCI) by intravascular ultrasound (IVUS) guidance~* Patients having coronary plaques (\>= 500 µm in thickness or 20% or more in % plaque) at \>= 5 mm from the previously treated area in the same branch of coronary artery~Exclusion Criteria:~* Patients with bypass graft or in-stent restenosis at the site of PCI~* Patients who had received PCI on the lesion in the past where the evaluation of coronary plaque volume is planned~* Patients who had plaques in a non-culprit site and might receive PCI during the treatment period~* Patients receiving lipid-lowering drugs (statins, fibrates, probucol, nicotinic acid or cholesterol absorption inhibitors)~* Patients with familial hypercholesterolemia~* Patients with cardiogenic shock~* Patients receiving cyclosporine~* Patients with any allergy to pitavastatin or atorvastatin~* Patients with hepatobiliary disorders~* Pregnant women, women suspected of being pregnant, or lactating women~* Patients with renal disorders or undergoing dialysis~* Patients who are ineligible in the opinion of the investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pitavastatin
- 2 (Type: ACTIVE_COMPARATOR): Atorvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).